The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008

Tuesday, August 19, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

LONDON and PHILADELPHIA, Aug. 18 Thomson Reuters, theworld's leading source of intelligent information for businesses andprofessionals, has announced the availability of the Pharma Matters reportscovering the time period January-March 2008. Launched more than two years ago,the quarterly Pharma Matters reports cover all aspects of the pharmaceuticalpipeline, leveraging strategic intelligence and competitive analysis fromThomson Pharma(R), Newport Horizon Premium(TM) and the Thomson MessagingMapping System(SM).

The Ones to Watch -- A Thomson Reuters quarterly review of the latestphase changes in the pharmaceutical pipeline, this report is based on thestrategic data and analysis from Thomson Pharma, the world's leadingpharmaceutical competitive intelligence solution. In the report covering Q12008, the top five most promising drugs launched or receiving approval were:

More analysis, as well as information on drugs entering clinical Phases I,II and III, are available in the full report:

(Due to the length of this URL, it may be necessary to copy andpaste this hyperlink into your Internet browser's URL address field. Removethe space if one exists.)

Movers and Shakers -- Introduced in mid-2007, this report is the newest inthe Pharma Matters series and covers the U.S. generics industry using data andanalysis from Newport Horizon Premium, the critical product targeting theglobal business development system. Analysis from the Q1 2008 report includes:

To learn more about companies making their mark on the U.S. genericsmarket, click on this link to read the full report:

(Due to the length, copy and paste URL into browser window.)

Who is Making the Biggest Splash? -- This report is a Thomson Reutersexpert review of the organizations that are helping to shape professionalopinions on drugs and therapies, using the unique insights of the ThomsonMessage Mapping System. In this quarterly review of the scientific literatureon drugs and therapies, Thomson Reuters assesses the quantity and quality ofthe materials published by pharmaceutical companies, research institutions andother non-commercial bodies. The top five of the listed 15 organizations thathave made the biggest impact as the leading sources of information on medicalresearch from January-March 2008 are:

To see the complete list, as well as analysis and methodology, click toread the full report:

(Due to the length, copy and paste URL into browser window.)

To sign up for the Thomson Reuters Pharma Matters series of publicationsvisit:

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent informationfor businesses and professionals. We combine industry expertise withinnovative technology to deliver critical information to leading decisionmakers in the financial, legal, tax and accounting, scientific, healthcare andmedia markets, powered by the world's most trusted news organization. Withheadquarters in New York and major operations in London and Eagan, Minnesota,Thomson Reuters employs more than 50,000 people in 93 countries. For moreinformation, go to DISEASE COMPANY Intelence(TM) HIV-1 infection Tibotec Pristiq(TM) Depression Wyeth Ionsys(TM) Acute pain ALZA Arcalyst(TM) CIAS1-associated Regeneron periodic syndromes Moxatag(TM) Streptococcus MiddleBrook

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store